160Indexed trials
canonical disease area
Multiple Sclerosis
Intelligence
Multiple Sclerosis intelligence: 160 indexed trials, 31 recruiting studies, 114 sponsors across 71 countries.
31Recruiting
114Sponsors
71Countries
Leading sponsors
Biogen61 recruiting
Hoffmann-La Roche62 recruiting
Teva Neuroscience, Inc.40 recruiting
Celgene40 recruiting
University of Calgary30 recruiting
Brigham and Women's Hospital30 recruiting
Tianjin Medical University General Hospital32 recruiting
Cairo University30 recruiting
Genzyme, a Sanofi Company30 recruiting
University Hospital, Basel, Switzerland32 recruiting
Amgen22 recruiting
IRCCS San Raffaele20 recruiting
Geographic activity
United States61trials
Canada21trials
Spain21trials
Poland20trials
Italy20trials
United Kingdom19trials
France16trials
Germany16trials
Czechia14trials
Belgium14trials
Switzerland14trials
China13trials
Leading interventions
Ocrelizumab9trials
Fingolimod4trials
Nabiximols3trials
Natalizumab3trials
Methylprednisolone2trials
Inebilizumab2trials
Dimethyl Fumarate2trials
Blood Draw2trials
Diroximel Fumarate2trials
Dimethyl fumarate2trials
Interferon beta-1a2trials
RPC10632trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.